Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$84.32

-1.08 (-1.26%)

17:08
10/19/16
10/19
17:08
10/19/16
17:08

BioMarin reports Phase 2 vosoritide data in dwarfism

BioMarin provided an update on its Phase 2 study of vosoritide in children with achondroplasia, the most common form of dwarfism, at the American Society of Human Genetics 2016 Meeting. Results from 8 children in cohort 4, who completed six months of daily dosing at 30 microgram/kg/daily experienced a 46% or 2.1 cm/year increase in mean annualized growth velocity from baseline. These data are comparable to those observed at the lower dose of 15 microg/kg/day in cohort 3, the company said. Results from 10 children in cohort 3, who completed six months of daily dosing at 15 microgram/kg/day experienced a 50% or 2.0 cm/year increase in mean annualized growth velocity from baseline. Vosoritide was generally well tolerated at all doses. All injection site reaction events were mild and transient. No new safety findings were observed at the 30 microg/kg/day dose. "The data support our use of the lower dose of 15 microgram/kg/day in the Phase 3 study," the company said, adding that "the company believes based on discussions with global health authorities that change in growth velocity from baseline as an endpoint could lead to registration. The company plans to augment these data with supportive evidence concerning proportionality and functionality."

  • 19

    Oct

  • 27

    Oct

  • 06

    Nov

  • 29

    Nov

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

BMRN BioMarin
$84.32

-1.08 (-1.26%)

09/21/16
LEER
09/21/16
NO CHANGE
LEER
Market Perform
Previous PTAB ruling remains overhang on Sarepta eteplirsen, says Leerink
Leerink analyst Joseph Schwartz notes that Sarepta (SRPT) has announced favorable Patent Trial and Appeal Board of the U.S. Patent and Trademark Office decisions in favor of its exon 51 and 53 composition of matter patent interference cases against BioMarin (BMRN). However, he points out that these rulings are subject to appeal and a previous ruling from the U.S. Patent Trial and Appeal Board, or PTAB, in favor of BioMarin's method of use patent remains an overhang on the commercialization of Sarepta's eteplirsen. The analyst reiterates a Market Perform rating on Sarepta's shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/14/16
BARD
10/14/16
NO CHANGE
Target $115
BARD
Outperform
BioMarin hemophilia drug update encouraging, says Baird
Baird analyst Michale Ulz said he is encouraged by BioMarin's update on its Phase 1/2 study of its Hemophilia A drug, BMN-270. The analyst noted U.K. regulators approved continued enrollment in the gene-therapy study and the study was amended to allow dose optimization ahead of the Phase 2b study expected in 2017. Ulz reiterated his Outperform rating and $115 price target on BioMarin shares.
10/17/16
JANY
10/17/16
NO CHANGE
JANY
PTC's denial has negative read-through for BioMarin, says Janney Capital
Janney Capital noted that PTC Therapeutics' (PTCT) Translarna and Sarepta's (SRPT) Exondys 51 address non-overlapping DMD populations and there was an expectation of flexibility from the FDA following the conditional approval of Exondys 51. However, the FDA has denied the first appeal of the refuse to file letter regarding PTC's NDA for Translarna for the treatment of nonsense mutation DMD, which the firm said has potential negative read-through for BioMarin's (BMRN) attempt to rekindle Kyndrisa, which is a direct competitor to Sarepta's Exondys 51. The firm added that the news might positively impact reimbursement decisions for Exondys 51.

TODAY'S FREE FLY STORIES

DRI

Darden

$83.14

0.26 (0.31%)

08:43
09/26/17
09/26
08:43
09/26/17
08:43
Hot Stocks
Darden says expects impact of Hurricane Irma to be double that of Harvey »

Says Irma impact factored…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

AMRS

Amyris

$3.21

-0.29 (-8.29%)

08:42
09/26/17
09/26
08:42
09/26/17
08:42
Hot Stocks
Amyris enters second product development, production agreement with Royal DSM »

Amyris announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VTR

Ventas

$66.62

0.58 (0.88%)

08:42
09/26/17
09/26
08:42
09/26/17
08:42
Conference/Events
The Executives' Club of Chicago holds a luncheon meeting »

The Executives' Club…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

08:40
09/26/17
09/26
08:40
09/26/17
08:40
General news
U.S. equities are mostly mildly firmer »

U.S. equities are mostly…

08:40
09/26/17
09/26
08:40
09/26/17
08:40
General news
Breaking General news story  »

Week of 9/23 Redbook to…

DRI

Darden

$83.14

0.26 (0.31%)

08:39
09/26/17
09/26
08:39
09/26/17
08:39
Hot Stocks
Breaking Hot Stocks news story on Darden »

Darden says Hurricane…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

NVDA

Nvidia

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Technical Analysis
Technical View: Nvidia bounces back from prior session losses »

The shares were last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VCYT

Veracyte

$8.49

0.01 (0.12%)

08:38
09/26/17
09/26
08:38
09/26/17
08:38
Recommendations
Veracyte analyst commentary  »

Veracyte visibility…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

DRI

Darden

$83.14

0.26 (0.31%)

08:36
09/26/17
09/26
08:36
09/26/17
08:36
Hot Stocks
Darden says all businesses 'remain strong' »

Says to-go sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

TEUM

Pareteum

$1.06

0.01 (0.95%)

08:35
09/26/17
09/26
08:35
09/26/17
08:35
Hot Stocks
Breaking Hot Stocks news story on Pareteum »

Pareteum Corp trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVEE

NV5 Global

$53.85

2.15 (4.16%)

08:34
09/26/17
09/26
08:34
09/26/17
08:34
Hot Stocks
NV5 Global awarded $14M program management contract by Merced County »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CSBR

Champions Oncology

$3.66

-0.09 (-2.40%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Champions Oncology awarded $2M from National Cancer Institute »

Champions Oncology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.96

0.03 (1.55%)

, UNIT

Uniti Group

$17.36

0.85 (5.15%)

08:33
09/26/17
09/26
08:33
09/26/17
08:33
Hot Stocks
Windstream says allegations in purported notice of default 'without merit' »

In a regulatory filing…

WIN

Windstream

$1.96

0.03 (1.55%)

UNIT

Uniti Group

$17.36

0.85 (5.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

OSIS

OSI Systems

$85.81

-1.08 (-1.24%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
OSI Systems receives $16M in orders for ETD systems »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Oct

AXON

Axovant Sciences

$24.25

-0.74 (-2.96%)

08:32
09/26/17
09/26
08:32
09/26/17
08:32
Hot Stocks
Breaking Hot Stocks news story on Axovant Sciences »

Axovant says Mindset…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

GILD

Gilead

$83.61

0.34 (0.41%)

, KITE

Kite Pharma

$179.31

0.01 (0.01%)

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Hot Stocks
Gilead, Kite Pharma announce expiration of HSR waiting period »

Gilead Sciences (GILD)…

GILD

Gilead

$83.61

0.34 (0.41%)

KITE

Kite Pharma

$179.31

0.01 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 12

    Feb

08:31
09/26/17
09/26
08:31
09/26/17
08:31
Conference/Events
Federal Reserve Bank of Atlanta President speaks on the economic outlook »

Atlanta Federal Reserve…

CAB

Cabela's

$61.50

0.03 (0.05%)

, SHOR

ShoreTel

08:30
09/26/17
09/26
08:30
09/26/17
08:30
Options
Two option delistings on September 26th »

Option delistings…

CAB

Cabela's

$61.50

0.03 (0.05%)

SHOR

ShoreTel

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:30
09/26/17
09/26
08:30
09/26/17
08:30
General news
U.S. Case-Shiller home prices preview: »

U.S. Case-Shiller home…

MSFT

Microsoft

$73.26

-1.15 (-1.55%)

08:29
09/26/17
09/26
08:29
09/26/17
08:29
Recommendations
Microsoft analyst commentary  »

Valuing Microsoft should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

08:29
09/26/17
09/26
08:29
09/26/17
08:29
Conference/Events
House Homeland Security Committee to hold a hearing »

The Oversight and…

SNX

Synnex

$116.50

0.4 (0.34%)

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Recommendations
Synnex analyst commentary  »

Synnex price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Subcommittee on…

RHT

Red Hat

$105.76

-0.54 (-0.51%)

08:28
09/26/17
09/26
08:28
09/26/17
08:28
Recommendations
Red Hat analyst commentary  »

Red Hat price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:27
09/26/17
09/26
08:27
09/26/17
08:27
Conference/Events
Senate Banking, Housing & Urban Affairs Committee to hold a hearing »

The Committee holds a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.